Osteopore Ltd. OSX

ASX · Australia · Health Technology

AUD 0.004000+0.00 (+33.33%)

Market closed· Oct 2, 2026, 4:55 AM UTC· AUD · Data may be delayed

Prices may be delayed and are for informational purposes only - not investment advice.

Osteopore Ltd. OSX

ASX · Australia · Health Technology

AUD 0.004000+0.00 (+33.33%)

Market closed· Oct 2, 2026, 4:55 AM UTC· AUD · Data may be delayed

Prices may be delayed and are for informational purposes only - not investment advice.

-33.33% · 6MFull-screen chart

Open AUD 0.004000High AUD 0.004000Low AUD 0.004000Close AUD 0.004000Volume 837.53K

Oct 2, 2026

Charts by TradingView Lightweight Charts

Key statistics

Previous close: AUD 0.003000
Day range: AUD 0.004000 – AUD 0.004000
52-week range: AUD 0.003000 – AUD 0.0290
Volume: 837.53K
Market cap: AUD 2.08M
Avg. volume (1Y): 4.50M

Performance

1 week

0.00%

1 month

-20.00%

3 months

-20.00%

6 months

-33.33%

Year to date

-38.46%

1 year

-66.67%

Total return, dividends included.

Company profile

Sector: Health Technology
Industry: Medical Specialties
Country: Australia
Exchange: ASX
Shares outstanding: 693.59M
ISIN: AU0000053324
Beta: 1.93

Technical view

Below averages

Where the price sits against its 50- and 200-day moving averages.

Valuation & analysis

Makkler Fair Value, financial health score, analyst view, peers and MakklerAI.

News

Yahoo FinanceNov 13, 2025

Kelyniam Global Secures Exclusive U.S. License for Evonik's VESTAKEEP® Fusion Biomaterial in Cranial Implants

CANTON, Conn., Nov. 13, 2025 (GLOBE NEWSWIRE) -- Kelyniam Global, Inc. (OTC: KLYG), a leader in custom cranial and craniofacial implants, today announced it has secured an exclusive U.S. license from Evonik Industries AG to market VESTAKEEP® Fusion, a bi-calcium phosphate-infused PEEK material, for cranial, craniofacial, and maxillofacial implants. This agreement grants Kelyniam two years of exclusivity with the option for renewal upon mutual agreement. The license enhances Kelyniam's regenerati

Recent third-party headlines about this company, kept separate from Makkler's own editorial coverage and linking out to the publisher. Accuracy is the publisher's responsibility.